You are viewing: UK Recombinant Proteins Market analysis
Part of: Recombinant Proteins Market (Global)

The UK Recombinant Proteins Market was valued at $6 Million in 2023 and projected to reach to $7.9 Million by 2028, representing a compound annual growth rate of 5.8%. The UK recombinant proteins market is positioned for sustained growth through 2028, supported by robust pharmaceutical infrastructure and increasing healthcare investment in advanced biotherapeutics.

UK Recombinant Proteins Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Recombinant Proteins Market Trends and Insights

  • The UK market benefits from strong pharmaceutical infrastructure, advanced research capabilities, and increasing demand for biotherapeutics across therapeutic areas including oncology, immunology, and rare diseases.
  • The UK's position as a leading biotech hub in Europe supports continued investment in recombinant protein development and manufacturing. Driving growth in the UK market are rising healthcare expenditures, growing prevalence of chronic diseases, and accelerating adoption of biologics in clinical practice.
  • The UK's regulatory framework through the MHRA and alignment with European standards facilitates faster market entry for recombinant protein therapeutics.
  • Additionally, the UK's robust contract manufacturing organization (CMO) sector and academic research institutions strengthen the competitive ecosystem for recombinant protein innovation and commercialization through 2028..

Key Market Statistics

  • CAGR (2023-2028) 5.8% CAGR
  • Market Size, 2023 ~USD 6 Million
  • Forecast, 2028 ~USD 7.9 Million
  • Country UK

UK Recombinant Proteins Market Overview

Market Valuation :

The UK recombinant proteins market was valued at $6.0 million in 2023 and is projected to reach $7.9 million by 2028, representing steady growth in the biopharmaceutical sector.

Growth Trajectory :

The UK market is expanding at a CAGR of 5.8%, driven by increasing adoption of recombinant protein therapeutics and growing investment in biotechnology infrastructure across the country.

Therapeutic Applications :

Key therapeutic areas driving UK market growth include oncology, immunology, and rare diseases, with NHS funding and private sector initiatives supporting biotherapeutic development and commercialization.

Research & Infrastructure :

The UK benefits from world-class pharmaceutical research institutions, established manufacturing capabilities, and regulatory frameworks that support innovation in recombinant protein development and clinical deployment.

UK Recombinant Proteins Market Dynamics

  • The NHS's commitment to precision medicine and the UK's post-Brexit regulatory independence are creating opportunities for accelerated drug development and commercialization.
  • Growing prevalence of chronic diseases, particularly in oncology and immunology, continues to drive demand for recombinant protein-based treatments.
  • Additionally, UK-based biotech companies and research institutions are strengthening their competitive position in global markets, attracting venture capital and fostering innovation ecosystems across major life sciences hubs..

Market Ecosystem

logo-mobile

RECOMBINANT PROTEINS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Recombinant cytokines and growth factors from its Gibco, Invitrogen, and PeproTech brands are used in cell culture, drug discovery, immunology research, stem cell expansion, and cell therapy manufacturing. Its GMP-grade proteins support the production of cell-based therapies. Supports reproducible cell culture and immune-cell expansion | Enables research-to-manufacturing workflows | Supports clinical manufacturing requirements through GMP-grade proteins.
company logo
Merck provides recombinant protein expression and process-development technologies for biopharmaceutical applications. Its CHOZN expression platform and associated process-development services support the development and scale-up of recombinant proteins and other biologics. Supports high-producing cell-line development | Facilitates process optimization and scale-up | Helps improve manufacturing productivity and consistency.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The UK recombinant proteins market is valued at $6.0 million in 2023 and will reach $7.9 million by 2028 at a 5.8% CAGR.
    • The UK's advanced biotech infrastructure and MHRA regulatory framework accelerate recombinant protein development and market entry.
    • Rising chronic disease prevalence and increased biologics adoption drive demand for recombinant protein therapeutics across the UK.
    • The UK's CMO sector and academic research institutions provide competitive advantages in recombinant protein innovation and manufacturing.

    Recombinant Proteins Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment INTERFERONS (IFNS) (Type)
    Forecast Period 2023-2028
    Growth Rate CAGR of 7.2% from 2023 to 2028
    Largest Segment PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 2.26 (2023)
    Revenue Forecast (Billions) ~USD 3.2 (2028)
    Segments Covered Product, Type, Application, Host Cell, End User

    UK Recombinant Proteins Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Other Recombinant Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins

    By Type

    • Academic Research
    • Biologics
    • Biotechnology Research
    • Cell & Gene Therapy
    • Interferons (Ifns)
    • Interleukins (Ils)
    • Other Growth Factors & Chemokines
    • Vaccines

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Discovery & Development
    • Other Applications
    • Research

    By Host Cell

    • Bacterial Cells
    • Insect Cells
    • Mammalian Systems
    • Other Cell Hosts
    • Other Host Cells
    • Yeast & Fungi

    By End User

    • Academic Research Institutes
    • Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028

    Segment20212022202320242025202620272028CAGR (%)
    ACADEMIC RESEARCH INSTITUTES25.526.227.93032.334.937.941.18
    BIOTECHNOLOGY COMPANIES17.918.419.620.922.524.326.428.67.9
    CONTRACT RESEARCH ORGANIZATIONS9.49.710.210.911.712.613.714.87.6
    OTHER END USERS66.16.46.77.27.68.28.76.5
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES50.151.755.159.263.969.175.181.78.2
    TOTAL108.85112.08119.23127.8137.56148.58161.17174.988

    Target Audience

    • Pharmaceutical Companies : UK and international pharma firms need market intelligence to assess commercial opportunities, plan product launches, and optimize pricing strategies within the UK recombinant proteins market.
    • Biotech & Life Sciences Firms : UK-based biotech companies require competitive benchmarking data and market forecasts to guide R&D investments, secure funding, and position their recombinant protein candidates for clinical success.
    • Healthcare Payers & NHS : NHS trusts and healthcare commissioners need market data to inform procurement decisions, budget planning, and health technology assessments for recombinant protein therapeutics.
    • Investment & Venture Capital : Investors and venture capital firms require UK market insights to identify high-growth opportunities, evaluate biotech portfolio companies, and make informed funding decisions in the recombinant proteins space.
    • Research Institutions & Academia : UK universities and research centers need market intelligence to align research initiatives with commercial demand, identify collaboration opportunities, and support technology transfer and commercialization efforts.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Obtain precise valuation data for the UK recombinant proteins market with detailed forecasts through 2028, enabling accurate budget allocation and market entry strategies tailored to the British healthcare landscape.
    • Competitive Intelligence : Identify key UK-based manufacturers, research institutions, and biotech companies operating in the recombinant proteins space, along with their market positioning and growth strategies.
    • Regulatory & Reimbursement Insights : Understand UK-specific regulatory pathways, NICE approval processes, and NHS reimbursement mechanisms that directly impact market access and commercial viability for recombinant protein therapeutics.
    • Therapeutic Area Deep-Dive : Analyze demand patterns across UK priority therapeutic areas including oncology, immunology, and rare diseases, with insights into clinical adoption rates and treatment paradigm shifts.
    • Investment & Partnership Opportunities : Discover funding trends, venture capital activity, and strategic partnership opportunities within the UK recombinant proteins ecosystem to inform investment decisions and collaboration strategies.

    Frequently asked questions

    What is the current size of the UK recombinant proteins market?

    The UK recombinant proteins market was valued at $6.0 million in 2023 and is expected to grow to $7.9 million by 2028.

    What is the projected growth rate for the UK recombinant proteins market?

    The UK recombinant proteins market is projected to grow at a CAGR of 5.8% from 2023 to 2028.

    What factors are driving growth in the UK recombinant proteins market?

    Key growth drivers include rising healthcare expenditures, increasing prevalence of chronic diseases, growing adoption of biologics, and the UK's strong biotech infrastructure and regulatory environment.

    How does the UK regulatory environment support recombinant protein development?

    The UK's MHRA regulatory framework and alignment with European standards facilitate faster market entry and approval for recombinant protein therapeutics.

    What role do UK contract manufacturers play in the recombinant proteins market?

    The UK's robust CMO sector provides manufacturing expertise and capacity that supports innovation and commercialization of recombinant protein therapeutics.

    RESEARCH METHODOLOGY

    This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global recombinant proteins market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.

    Secondary Research

    The secondary sources referred to for this research study include publications from government sources,such as the World Health Organization, The Antibody Society,Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC),National Center for Biotechnology Information (NCBI), American Medical Association (AMA), RecombinantAntibody Network (RAN), National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), and the Institute for Molecular Medicine, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

    Recombinant Protein Market 
 Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The top-down and bottom-up approaches were used to estimate & validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various market segments.

    Recombinant Protein Market Top Down and Bottom Up Approach

    Data Triangulation

    After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.

    Market Definition

    Recombinant proteins are manipulated proteins generated by recombinant DNA technology that modifies gene sequences. These are formed by transfecting foreign genes into a host cell. Recombinant proteins are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses. This market includes recombinant protein products, including growth factors, cytokines, recombinant enzymes, structural proteins, and membrane proteins.

    Key Stakeholders

    • Pharmaceutical & Biopharmaceutical Companies
    • Biotechnology Companies
    • Life Sciences Companies
    • Academic Research Institutes
    • Government Institutes
    • Private Research Firms
    • Contract Research Organizations (CROs)
    • Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
    • Venture Capitalists and Investors
    • Market Research and Consulting Firms

    Report Objectives

    • To define, describe, and forecast the recombinant proteins market based on product, host cell, application, and end user
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall recombinant proteins market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders  
    • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To strategically profile the key players in the recombinant proteins market and comprehensively analyze their core competencies and market rankings
    • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the recombinant proteins market
    • To benchmark players within the recombinant proteins market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe recombinant proteins market, by country
    • Further breakdown of the Rest of Asia Pacific recombinant proteins market, by country
    • Further breakdown of the Rest of Latin America recombinant proteins market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

     

    Get the Full Recombinant Proteins Market Report

    Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status